{"id":543,"date":"2026-08-23T08:08:55","date_gmt":"2026-08-23T08:08:55","guid":{"rendered":"https:\/\/noimfine.com\/sph06\/?p=543"},"modified":"2026-09-23T08:09:38","modified_gmt":"2026-09-23T08:09:38","slug":"cavhanza-nilotinib-fda-approves-orally-disintegrating-tablet-for-adults-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia-2","status":"publish","type":"post","link":"https:\/\/noimfine.com\/sph06\/2026\/08\/23\/cavhanza-nilotinib-fda-approves-orally-disintegrating-tablet-for-adults-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia-2\/","title":{"rendered":"Cavhanza (Nilotinib): FDA Approves Orally Disintegrating Tablet for Adults With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia"},"content":{"rendered":"<div><!--[--><!--&gt;--><\/p>\n<div>\n<div>\n<div>\n<div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<div>\n<div>\n<section>\n<h2><\/h2>\n<p><a href=\"https:\/\/www.webmd.com\/drugs\/cavhanza-nilotinib\">Cavhanza (nilotinib)<\/a> is a new FDA-approved orally disintegrating tablet (ODT) formulation of nilotinib, a prescription medicine used to treat a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).The FDA has approved Cavhanza for adults with newly diagnosed chronic-phase Ph+ CML as well as for those with chronic- or accelerated-stage disease who have not responded or are intolerant to prior treatments such as imatinib.Cavhanza is a second-generation tyrosine kinase inhibitor (TKI) that works by blocking the BCR\u2011ABL protein, keeping it in the \u201coff\u201d state to slow down the growth of leukemic cells.<iframe src=\"https:\/\/www.youtube.com\/embed\/0TpI168MF7Q\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>Around 25% of patients with Ph+ CML use medicines such as proton pump inhibitors (PPIs) or H\u2082 blockers (H\u2082RAs) to treat common conditions including acid reflux or heartburn.<iframe src=\"https:\/\/www.youtube.com\/embed\/7eKdNwSWGug\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>However, with older forms of nilotinib, these acid-suppressing medicines and even food can affect how well the nilotinib is absorbed, making dosing more complicated and less predictable.<iframe src=\"https:\/\/www.youtube.com\/embed\/LT_PcAl59tQ\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>According to the drugmaker, the ODT form of Cavhanza is designed for easy use and more reliable absorption, remaining effective even when taken with PPIs or H\u2082RAs, without requiring strict timing rules. This approval matters, as the ODT form of Cavhanza can be taken with or without food, offering more flexible dosing. Because the tablet dissolves in the mouth and can be taken with or without water, it may help patients who have a hard time swallowing pills, making it easier to continue their therapy.<\/section>\n<section>\n<h2>Why Was It Approved?<\/h2>\n<p>The FDA\u2019s approval of the ODT version of Cavhanza (with its twice-daily dosing schedule) was supported by proven safety and effectiveness data from well-controlled studies of the capsule form of nilotinib for treating adults with newly diagnosed chronic-phase Ph+ CML. The clinical responses supported Cavhanza\u2019s use for adults with newly diagnosed chronic-phase Ph+ CML as well as for those who were resistant or intolerant to prior therapy, including imatinib. The studies showed no difference in the rate or extent of nilotinib absorption whether the ODT was swallowed whole or allowed to dissolve in the mouth before swallowing.<\/section>\n<\/div>\n<div>\n<section>Studies showed that Cavhanza delivered nilotinib into the body in a way that was comparable to the existing approved formulation and\u00a0provided consistent absorption and efficacy even when taken with food and commonly used stomach acid-reducing medications. The most common side effects seen in patients included nausea, vomiting, diarrhea, constipation, skin rash, itching, headache, tiredness, coughing, muscle or joint pain, cold-like symptoms, fever, hair loss (alopecia), and night sweats. Some patients also had blood count issues, including low platelets, low white blood cells, and low red blood cells (anemia). Serious side effects can include an abnormal heart rhythm (prolonged QT interval), sudden death, low white blood cell counts with a fever, heart-related problems and blocked arteries, bleeding in the brain, and tumor lysis syndrome.<\/section>\n<section>\n<h2>What Do I Need to Know?<\/h2>\n<p>The recommended Cavhanza dose is 120 mg twice daily for patients with newly diagnosed chronic-phase Ph+ CML and 160 mg twice daily for those with chronic- or accelerated-phase Ph+ CML who are resistant or intolerant to prior therapy; the dose can be taken with or without food. Take the two doses about 12 hours apart. Let the tablet dissolve on your tongue and then swallow it, or you may chew and swallow it or swallow the ODT whole with water. If you miss a dose, skip it and take the next dose at your usual time. Do not take two doses together. Do not eat or drink grapefruit products while taking Cavhanza. Your health care provider will check your heart rhythm with an electrocardiogram (EKG) before starting treatment, again about a week after the first dose, and from time to time afterward, including after any change in dose. They may also run tests to check your uric acid levels and blood counts before starting Cavhanza and monitor your fluid levels during treatment. Let your health care provider know if you have any liver or heart issues, or pancreas-related problems, as Cavhanza can increase the risk of liver or pancreatic injury. Also let them know if you have low potassium or magnesium levels or if you have long QT syndrome.<\/section>\n<\/div>\n<div>\n<section>Be sure to let your health care provider know about all the prescription medicines, over-the-counter products, herbal remedies (such as St John\u2019s wort), and supplements you take. Medicines that significantly affect drug-processing liver enzymes, such as CYP3A inducers and CYP3A inhibitors, can substantially affect Cavhanza levels. Avoid combining Cavhanza with medicines that can prolong the QT interval or with strong CYP3A4 inhibitors. If a strong inhibitor cannot be avoided, your dose may need to be lowered and EKGs done more often. Cavhanza may harm a fetus. Use effective birth control during treatment and for 14 days after the last dose. Do not breastfeed during treatment and for 14 days after the last dose. Cavhanza can lower platelet and neutrophil counts and cause anemia. Call your health care provider if you have a fever, unusual bleeding or bruising, unexplained weakness, signs of infection, or shortness of breath. Contact your health care provider right away if you have abnormal or irregular heartbeats, light-headedness, chest or leg pain, numbness or weakness, sudden problems in walking or speaking, sudden pain in the stomach area along with nausea or vomiting, yellowing of the skin and eyes with dark-colored urine, rapid weight gain or ankle swelling, reduced urine output, vision changes, or a sudden headache or confusion. These could be signs of serious side effects. Cavhanza is launching soon and is supported by Cycle Vita, a dedicated patient support program that may have eligibility rules.<\/section>\n<\/div>\n<\/div>\n<p><!--&gt;<\/div>\n\n\n--><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cavhanza (nilotinib) is a new FDA-approved orally disintegrating tablet (ODT) formulation of nilotinib, a prescription medicine used to treat a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).The FDA has approved Cavhanza for adults with newly&#8230; <\/p>\n","protected":false},"author":2,"featured_media":215,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-543","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/comments?post=543"}],"version-history":[{"count":1,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/543\/revisions"}],"predecessor-version":[{"id":544,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/543\/revisions\/544"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media\/215"}],"wp:attachment":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media?parent=543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/categories?post=543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/tags?post=543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}